Drug extravasation along the route of a peritoneal catheter during intraperitoneal chemotherapy
- 15 October 1987
- Vol. 60 (8) , 1731-1733
- https://doi.org/10.1002/1097-0142(19871015)60:8<1731::aid-cncr2820600808>3.0.co;2-4
Abstract
A patient receiving intraperitoneal chemotherapy with cisplatin and cytosine arabinoside developed an abdominal skin rash similar in appearance to Cullen's sign. She subsequently received intraperitoneal mitoxantrone, which became visible in the skin close to the peritoneal catheter tract in the region of the skin rash within 24 hours of drug administration. There was no evidence for drug extravasation from the entry portal of the peritoneal catheter or visible fluid leakage. Although the clinical picture was dramatic there was no significant clinical sequela to the extravasation of these drugs. The potential significance of this event is discussed.This publication has 19 references indexed in Scilit:
- Mitoxantrone: A New Anticancer Drug with Significant Clinical ActivityAnnals of Internal Medicine, 1986
- Catheter complications associated with intraperitoneal chemotherapyGynecologic Oncology, 1986
- Unreviewed ReportsBMJ, 1986
- Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantroneCancer Chemotherapy and Pharmacology, 1986
- Peritoneal Access for Intracavitary ChemotherapyCancer Drug Delivery, 1986
- Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity.Journal of Clinical Oncology, 1985
- Drug Extravasation as a Complication of Venous Access PortsAnnals of Internal Medicine, 1985
- Infectious peritonitis in patients receiving intraperitoneal chemotherapyThe American Journal of Medicine, 1985
- Totally implantable system for peritoneal access.Journal of Clinical Oncology, 1984
- Intra-Arterial and Intracavitary Cancer ChemotherapyPublished by Springer Nature ,1984